Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Record Third Quarter Revenue of $45.6 Million, Representing 18% Growth versus Prior Year
MACI Revenue Growth of 21% to $37.6 Million
Related news for (VCEL)
- Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
- Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
- Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
- vericel announces fda approval and commercial availability of maci arthro
- vericel announces fda approval of nexobrid for the treatment of pediatric patients with severe thermal burns